R&D channel feed – Endpoints News

R&D channel feed

PTC shares rocket up as European regulators offer a thumbs-up on Duchenne drug marketing

9 years ago

Kleiner Perkins-backed Elcelyx says its reformulated metformin worked in a PhIIb diabetes study

9 years ago

Bristol-Myers scores fresh bragging rights with PhIII gastric cancer success for Opdivo

9 years ago

Cell Medica signs up for an off-the-shelf CAR-T collaboration with Baylor

9 years ago

AstraZeneca axes another R&D track on durvalumab after once again falling behind rivals

9 years ago

Crushed by a PhIII flop, Novavax slashes jobs as it looks to chop out up to $100M in costs

9 years ago

Celgene EVP Rich Bagger makes Politico’s short list for Trump’s Cabinet

9 years ago

Kite gives itself a little more time to finish FDA application for KTE-C19

9 years ago

As election storm gathered, Arrowhead drops word about a clinical hold

9 years ago

CureVac grabs a $29.5M round to fuel its mRNA development efforts

9 years ago

Versant’s global biotech team is reloading with $350M-plus fund

9 years ago

Cardio event forces FDA to halt a Penn PhII study for multiple myeloma

9 years ago

Cardio drug at The Medicines Co gets the heave-ho. (But they prefer PCSK9 anyway.)

9 years ago

Roche flags early success for Tecentriq combos, hustles into PhIIIs

9 years ago

Poised to launch a new drug for SMA, Biogen and Ionis shares jump on more promising PhIII data

9 years ago

Sanofi jumps into a pivotal study for next-gen Pompe drug

9 years ago

Nestlé invests $145M in Aimmune’s food allergy R&D work, taking the head seat at the deal table

9 years ago

Celyad chief blasts Cellectis’ CEO Choulika, claiming he lied about CAR-T patent

9 years ago

The losers are piling up after today’s big ASH abstract drop

9 years ago

Spark Therapeutics shares slide after a setback on its hemophilia gene therapy study

9 years ago

Investigators sound a safety alarm after 2 patients die of heart condition following checkpoint combo

9 years ago

Merck can’t prove its Alzheimer’s drug works, yet, but it did just explain why it’s spending a fortune on PhIII

9 years ago

Severe adverse events mar the end of Roche’s PhIII for ‘breakthrough’ hemophilia drug

9 years ago

PTC sees higher regulatory risk in fight to keep its Duchenne drug on the European market

9 years ago

First page Previous page 311 312 313314315 316 317 Next page Last page